Benda Pharmaceutical, Inc's Ebei plant received Good Manufacturing Practices (GMP) certification for its new tablets product line on November 26, 2007. The GMP certification clears the tablets for mass production and sale, marking the official conclusion of the plant's dramatic capacity expansion and beginning its significant product line growth.

The Ebei plant is currently Benda's most significant revenue contributor and forms the solid base upon which Benda is launching next generation biopharmaceuticals like Gendicine, according to a company statement. Ebei achieved $11.8 MM in revenue during the first nine months of 2007, a 55 per cent increase over the same period a year ago. The Ebei plant has been primarily engaged in producing and distributing conventional medicines in injection vial form.

To both grow and diversify the plant's business, Benda began in September 2006 the construction of an addition to the plant intended to house multiple new production lines. The company completed construction in September 2007. The new addition adds to the product mix five new production lines, with respective annual capacities of 40 million oral liquid vials, 230 million capsules, 758 million tablets, 500 tons of pills and 20 million bags of granules.

On November 26, 2007 the tablets line became the first to receive GMP certification, valid for a 5-year period. The Ebei plant started the full production and sale of tablets in late December 2007; Benda expects the new tablets line alone to contribute approximately $1.8 million in revenue in 2008. The four remaining product lines are all under GMP review and the Company expects each to be certified in early 2008.

"This capacity expansion and addition to Ebei's product mix has been long-anticipated and represents an important milestone for Benda," commented Mr. Yiqing Wan, chairman and CEO, Benda. "Gendicine has deservedly garnered most of the public's attention of late, but much of the drug's future growth will be made possible by the continued success of our stable, profitable product lines. Our investment in the Ebei plant will ultimately yield an even stronger base from which to launch Gendicine into India and beyond."

Benda Pharmaceutical, Inc, a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure.